Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes.
NCT ID: NCT06373653
Last Updated: 2025-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2025-02-11
2025-02-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes
NCT06859476
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
NCT06375343
Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201
NCT05470881
Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution
NCT05481489
Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.
NCT01871077
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
-Analog visual eyestrain test score
Secondary:
* Incidence of unexpected adverse events related to the interventions
* Incidence of conjunctival hyperemia
* Incidence of sensation of ocular dryness
* Incidence of ocular irritation
* Incidence of sensation of (sleep-crust)
* Incidence of sensation of comfort with the application, when applied by the Principal Investigator (PI)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Manzanilla Sophia®
Matricaria recutita 0.025%, Ophthalmic solution.
* Dosage: 1 drop every 4 hours (4 daily applications \[QID\]), during 7 days.
* Route of administration: Topical ophthalmic.
Manzanilla Sophia®
Matricaria recutita 0.025%, Ophthalmic solution.
Meticel Ofteno®
Hypromellose 0.5%. Ophthalmic solution.
* Dosage: 1 drop every 4 hours (4 daily applications \[QID\]), during 7 days
* Route of administration: Topical ophthalmic.
Meticel Ofteno®
Hypromellose 0.5%, Ophthalmic solution.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Manzanilla Sophia®
Matricaria recutita 0.025%, Ophthalmic solution.
Meticel Ofteno®
Hypromellose 0.5%, Ophthalmic solution.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.
* Age ≥18 years.
* Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO \[Tubal Ligation\]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form \[ICF\]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.
* Present on the analog visual eyestrain test score ≥ 3 on at least 4 of the included questions.
Exclusion Criteria
* Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.
* In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.
* Having participated in any clinical research study 30 days prior to inclusion in this study.
* Having previously participated in this same study.
* Having a single functional eye.
* Having a history of drug addiction or drug dependence current or within the last two years prior to signing the informed consent.
Elimination Criteria:
* Withdrawal of their consent to participate in the study (informed consent form).
* Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures.
* Non-tolerability or hypersensitivity to any of the drugs under investigation.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratorios Sophia S.A de C.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SOPHMAN-0922/IV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.